Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Leases: 2021-2025

Historic Operating Leases for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $7.0 million.

  • Kiniksa Pharmaceuticals International's Operating Leases fell 18.01% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 18.01%. This contributed to the annual value of $7.9 million for FY2024, which is 21.42% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Operating Leases stood at $7.0 million for Q3 2025, which was down 3.05% from $7.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Operating Leases' 5-year high stood at $11.3 million during Q2 2023, with a 5-year trough of $1.3 million in Q2 2022.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Operating Leases had a median value of $8.6 million in 2024 and averaged $8.3 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Operating Leases crashed by 63.49% in 2022, and later spiked by 782.86% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Operating Leases (Quarterly) stood at $2.7 million in 2021, then fell by 1.91% to $2.6 million in 2022, then spiked by 282.16% to $10.0 million in 2023, then dropped by 21.42% to $7.9 million in 2024, then dropped by 18.01% to $7.0 million in 2025.
  • Its Operating Leases stands at $7.0 million for Q3 2025, versus $7.2 million for Q2 2025 and $7.6 million for Q1 2025.